JPRN-jRCT2080224717已完成1 期
A Phase 1a / 1b, First-in-human, Open-label,Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients with Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with unresectable advanced solid tumors who have shown disease progression after receiving standard/ approved chemotherapy
- •Patients with unresectable advanced solid tumors and one of the following tumor types:
- •a. Have progressed after IO therapy and are felt to be appropriate for this type of treatment
- •b. Have EGFR+ NSCLC and have demonstrated recent progression on <=2 lines of oral TKIs and are felt to be appropriate for this type of treatment.
- •c. Have BRAF-, KRAS-, or NRAS-mutated CRC, have received no more than 3 previous lines of treatment, and for whom there is no standard therapy remaining
- •d. Have persistent/recurrent ovarian cancer who would be platinum refractory/ resistant and have had any number of lines of prior therapy
- •e. Have BRAF-mutated or BRAF wild-type melanoma that has progressed following IO therapy or a combination BRAF/MEK inhibitor therapy
排除标准
- •- Severe heart disease, lung disease, or seizure disease that require treatment with antiepileptic drugs
- •- Major surgery or radiation therapy within 2 weeks prior to the start date
- •- Significant surgery to the gastrointestinal tract that could impair absorption
- •- Pregnant or nursing
研究者
相似试验
进行中（未招募）
1 期
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in participants with selected advanced or metastatic solid tumors.Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)CTIS2023-507305-33-00Astrazeneca AB204
进行中（未招募）
1 期
A Phase 1 study of anti-HER3 monoclonal antibody GSK2849330, in subjects with advanced HER3-positive solid tumors.EUCTR2013-001699-39-NLGlaxoSmithKline Research Development Ltd154
已完成
2 期
A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumorsgastric/gastroesophageal cancerhead and neck canceror NSCLCstage III-IV melanoma10027655NL-OMON44080GlaxoSmithKline40
进行中（未招募）
1 期
First trial testing safety and efficacy of IMGN151 in women with recurrent endometrial and ovarian cancerRecurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersMedDRA version: 20.0Level: PTClassification code: 10016180Term: Fallopian tube cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061328Term: Ovarian epithelial cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014736Term: Endometrial cancer recurrent Class: 100000004864CTIS2023-506842-22-00Immunogen Inc.259
撤回
1 期
A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapiesSolid tumor malignanciesCancer - Any cancerACTRN12623000202662Qurgen Australia Pty Ltd48